• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Efficacy and safety of the Chinese herbal medicine shuganjieyu with and without adjunctive repetitive transcranial magnetic stimulation (rTMS) for geriatric depression: a randomized controlled trial

    2015-12-09 05:19:36MinminXIEWenhaiJIANGHaiboYANG
    上海精神醫(yī)學(xué) 2015年2期
    關(guān)鍵詞:單用經(jīng)顱中草藥

    Minmin XIE, Wenhai JIANG,2*, Haibo YANG,2

    Efficacy and safety of the Chinese herbal medicine shuganjieyu with and without adjunctive repetitive transcranial magnetic stimulation (rTMS) for geriatric depression: a randomized controlled trial

    Minmin XIE1, Wenhai JIANG1,2*, Haibo YANG1,2

    shuganjieyu; Chinese herbal medicine; repetitive transcranial magnetic stimulation; geriatric depression; China

    1. Background

    Depression is a common mental disorder and a leading cause of disease burden in the elderly population.According to data from the World Health Organization,the prevalence of depression in elderly individuals is between 3 and 10%.[1]Geriatric depression usually refers to depression among individuals 60 years of age or older.[2]Slow onset and atypical symptoms (e.g.,relatively mild depressive symptoms and frequent concurrent somatic symptoms) are common in geriatric depression, which makes it easy to overlook. Failure to identify and treat geriatric depression can exacerbate the decline in physical functioning due to concurrent physical illnesses, increase the level of disability, and,thus, substantially decrease the individual’s quality of life.[3]

    Using a selective serotonin re-uptake inhibitor (SSRI)is the recommended first-line treatment for geriatric depression in most high-income countries. But these medications have many side-effects – some of which are serious[4]– that increase in prevalence and severity with increased dosage and that may be more prevalent and less tolerated in elderly individuals. The initial dose of antidepressant medication used for geriatric depression is usually relatively low due to clinicians’ concerns about serious side effects or interactions with other medications being used for physical illnesses. Partly due to this reason (i.e., using sub-optimal dosages),the treatment effect of common antidepressants in geriatric depression is not as robust as that in younger adults; moreover, geriatric patients who consider the medications less effective are often non-compliant with anti-depressant treatment. Many of these untreated or inadequately treated individuals become chronically depressed.

    Chinese herbal medicines have been widely used in the treatment of depression. Shuganjieyu, which is composed of St. John’s wort and extracts of Siberian ginseng, is the first Chinese herb-based medication approved by the Chinese drug regulatory agency(CFDA) for the treatment of depression (approved in 2008). It has been shown to be effective, safe, and well tolerated.[5-7]The main ingredients of shuganjieyu are hypericum perforatum and acanthopanax extract. The antidepressant effect of hypericum perforatum, which has a mechanism of action similar to that of SSRIs, has been well recognized.[8]Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive intervention that has also been shown to be a safe and effective treatment for depression in China and abroad.[9-11]This study aims to evaluate the efficacy and safety of shuganjieyu for geriatric depression when used with or without adjunctive treatment with rTMS.

    2. Methods

    2.1 Sample

    Figure 1 shows the enrollment of subjects in the study.Study participants were 79 patients with geriatricdepression admitted to the Third Hospital of Daqing Municipality between December 2013 and September 2014. The inclusion criteria were as follows. (a) Met the diagnostic criteria for depression according to the 10thedition of the International Classification of Diseases(ICD-10)[12]and had not been taking antidepressants in the two weeks prior to enrollment. (b) Met the classification of ‘liver stagnation and spleen deficiency’based on Traditional Chinese Medicine theories.[13][Symptoms of stagnated liver energy (‘qi’) include uncoordinated mood and will, lack of aspiration, and low mood; symptoms of spleen deficiency include emotional distress, restlessness, poor memory,insomnia, dizziness and poor appetite.] (c) Aged 60 years or older. (d) Scored no less than 18 points on the 17-item version of the Hamilton Rating Scale for Depression (HAMD-17).[14](e) Were willing to participate and signed the informed consent form (or their guardian signed the consent form). (f) Were in good physical health based on the baseline physical examination,electrocardiogram (EKG), clinical laboratory test results,and medical history. Exclusion criteria included (a)having suicidal tendencies; (b) the presence of serious heart, liver, or kidney dysfunction or any disease of the endocrine system; (c) had a history of epilepsy; (d)had a history of psychoactive substance dependence(including alcohol); (e) had depression induced by other mental or physical conditions; (f) had a bipolar disorder; (g) were unfit for rTMS treatment; (h) were allergic to hypericum perforatum or acanthopanax; (i)had abnormal EKG or laboratory test results; (j) had a history of poor medication compliance; or (k) had received electroconvulsive therapy in the month prior to enrollment.

    Figure 1. Flowchart of the study

    2.2 Intervention

    Patients who met the inclusion criteria were randomly assigned to the experiment or control group using a random number table. Shuganjieyu provided by Chengdu Kanghong Pharmaceuticals Co. Ltd., (China SFDA No. Z20080580) were used in the study. Patients in both groups received two capsules of shuganjieyu immediately after meals, twice a day for six weeks.Participants in the experiment group were also treated with rTMS (using equipment from the Magstim Co.,Ltd, UK) with the coil located above the left dorsolateral prefrontal cortex; participants in the control group were given mock-rTMS in which the coil touched the scalp but no stimulation was provided. The rTMS stimulation was of low intensity (30% MT) and low frequency (10HZ).Each session lasted for an average of 20 minutes. A total of 20 rTMS sessions were administered in four 5-day cycles with 2-day breaks between cycles. All participants and evaluators were masked during the trial. For patients who experienced sleep problems during the treatment, zopiclone or benzodiazepines were allowed for short-term treatment.

    2.3 Assessment of efficacy

    The Hamilton Rating Scale for Depression-17 Item(HAMD-17) was used to assess efficacy and the Treatment Emergent Symptom Scale (TESS) was used to assess safety.[14]The two scales were administered at 1 week, 2 weeks, 4 weeks, and 6 weeks after the initiation of the treatment. The reported inter-rater reliability of the Chinese version of HAMD-17, based on the correlation of total scores between independent raters, is between 0.88 and 0.99 and its validity, based on the correlation or the total score and clinical ratings of the severity of depression, is 0.92.[15]Two trained associate senior clinicians conducted these evaluations in this study; the inter-relater reliability of their HAMD-17 total was good (Kappa 0.75 to 0.86). Routine blood tests, tests of liver and kidney function, and EKGs were also assessed at the same time periods.

    The main measure of efficacy was the percent reduction from baseline HAMD-17 scores ([pretreatment score - post-treatment score]/pretreatment score x 100%) at the end of the trial. Efficacy was categorized into remitted (reduction >75% or total HAMD-17 score <7), significantly improved(reduction=50 to 74%), improved (reduction=25 to 49%), and not improved (reduction <25%).

    The HAMD-17 can be divided into 5 subscales:[16,17](a) 4 items in the retardation subscale assess depressed mood, work and activities, psychomotor retardation,and loss of sexual interest; (b) 3 items assess guilt,suicidal ideation, and psychomotor agitation; (c) 3 items assess sleep problems including difficulty of falling asleep, light sleep, and early awakening; (d) 6 items assess anxiety and somatic symptoms including mental anxiety, somatic anxiety, gastrointestinal symptoms,hypochondriasis, insight, and general somatic symptoms. And (e) 1 item assesses loss of weight.

    2.4 Statistical analysis

    SPSS 19.0 was used for data analysis. Means and standard deviations were provided. ANCOVA and repeated measures ANOVA (for HAMD-17 scores) were used to compare differences over time and cross groups.Two-sample t-test was used to compare cross-group differences and one-sample t-test was used to assess within-group differences (i.e., compared to baseline).Chi-squared test was used to compare categorical variables and Mann-Whitney rank test was use to compare continuous variables that were not normally distributed.

    3. Results

    3.1 Characteristics of participants

    Figure 1 shows the flowchart for the study. A total of 65 patients met the inclusion criteria, among whom 36 were assigned to the experiment group and 29 to the control group. In the experiment group, 1 patient dropped out from the study due to early hospital discharge; in the control group the diagnosis was changed to schizophrenia 1 week after admission in 1 patient and another 2 patients dropped out of the study because of early hospital discharge. Therefore, the final analysis included 35 individuals in the experiment group and 26 in the control group. The study completion rate was 97.2% (35/36) in the experimental group and 89.7% (26/29) in the control group. Table 1 shows the characteristics of the individuals who completed the 6-week study; there are no significant differences in gender, age, duration or illness or baseline total HAMD-17 total score between the two groups.

    3.2 Comparison of efficacy

    As shown in Table 2, based on the results of the repeated measures ANOVA, there were no significant cross-group differences (F=0.46,p=0.502) or differences in group-time interaction (F=1.07,p=0.352) in HAMD-17 total scores. However, HAMD-17 scores changed significantly over time (F=395.91,p<0.001). There was a gradual decrease in the measured severity of depressive symptoms over the six weeks of treatment that was similar in the two groups; by the end of the 6 weeks the mean HAMD-17 score in both groups had dropped by more than 37%.

    At the end of the trial (after 6 weeks of treatment),the two groups had similar efficacy. Using the classification system described in the methods section based on the percent change in the baseline HAMD-17 score, among the 35 patients in the experimental group who completed the 6 weeks of treatment, 1 had fully remitted, 6 were significantly improved, 27 were improved, and 1 was unchanged; thus the overall efficacy was 97.1% (34/35). Among the 26 patients in the control group who completed the treatment,1 had fully remitted, 4 were significantly improved,20 were improved, and 1 was unchanged; thus the overall efficacy was 96.2% (25/26). However, among the 61 patients from both groups who completed 6 weeks of treatment, only 2 (3.3%) remitted and only a further 10 (16.4%) had significant improvement; the remaining 80.3% (49/61) had less than 50% reduction in their baseline HAMD-17 scores. That is, by the end of the trial only 20% (7/35) of experimental groups subjects and 19% (5/26) of control groups subjects had experienced significant improvement (or remission) of their depressive symptoms.

    Table 1. Characteristics of study participants

    Table 2. Comparison of mean (sd) Hamilton Depression Rating Scale (HAMD-17) scores andthe percent change in the scores from baseline during the 6 weeks of treatment in theexperimental and control groupsa

    Table 3. Comparison of mean (sd) factors scores of Hamilton Depression Rating Scale (HAMD-17)before and after treatment in the experimental and control groupsa

    Table 3 presents comparisons of the five HAMD-17 subscale scores. All of the subscales showed a dramatic drop in the mean scores over the 6 weeks of the trial,but there were no significant differences between the experimental and control groups in the magnitude or pace of the improvement. There were some minor differences in the rate of improvement for the five subscales: after 1 week of treatment, the improvement in sleep and anxiety/somatic symptoms had already become statistically significant, the improvement in weight loss was only significant in the control group,the improvement in the ‘guilt, suicidal ideation,and agitation’ subscale was only significant in the experimental group, and neither of the groups showed statistically significant improvement in psychomotor retardation. However, by the end of the second week of treatment both groups showed statistically significant improvement over baseline in all five HAMD-17 subscales scores.

    3.3 Comparison of safety

    No severe adverse events occurred during the trial.Most adverse events occurred early in the study.There were a total of 15 events in 14 individuals (40%)in the experiment group: 2 had dry mouth (5.7%), 3 had headaches or discomfort in the head (8.6%), 2 experienced dizziness (5.7%), 3 had constipation (8.6%),3 had nausea (8.6%), 1 had excessive sweating (2.9%),and 1 had poor appetite (2.9%). There were a total of 13 events in 13 individuals (50%) in the control group:3 had dry mouth (11.5%), 2 had headaches (7.7%),4 experienced dizziness (15.4%), 1 had a stuffy nose(3.85%), 1 had constipation (3.9%), 1 had diarrhea(3.9%), and 1 had poor appetite (3.9%). All of these adverse events remitted spontaneously without any treatment; none of them were severe enough to require discontinuation of the treatment. The proportions of patients in the experimental and control groups who experienced adverse events were not statistically significant (40% v. 50%;χ2=0.605,p=0.437).

    4. Discussion

    4.1 Main findings

    In this double-blind randomized controlled trial that used changes in HAMD-17 total scores as the main outcome measure, we found comparable effectiveness of the Chinese herbal medicine shuganjieyu with or without adjunctive rTMS in the inpatient treatment of geriatric depression. Ninety-four percent (65/69) of the enrolled subjects completed the 6-week trial. None of the patients experienced serious side effects. Minor side effects occurred in 40% of patients treated with shuganjie and rTMS (the experimental group) and in 50% of patients treated with shuganjie and sham rTMS(the control group); all of these side effects resolved spontaneously and none of them required withdrawal from the study. We conclude that combined treatment with shuganjieyu and rTMS is safe.

    Improvement in depressive symptoms was progressive over the 6-week trial; by the end of the 6 weeks the mean overall HAMD-17 score had dropped by 38% in the experimental group and 37% in the control group. The failure to identify a significant time by group interaction in the repeated measures ANOVA suggests that rTMS does not result in a more rapid onset of treatment, as has been suggested by other authors.[11]Using a drop in HAMD-17 score from baseline of 25%or greater as the cutoff for ‘efficacy’, by the end of the trial efficacy was 97% in the experimental group and 96% in the control group. However, using a drop in the HAMD-17 score from baseline of 50% or greater as the cutoff for ‘significant improvement’, only 20% (7/35) of the patients in the experimental group and 19% (5/26)of the patients in the control group had a significant improvement in their depressive symptoms by the end of the 6 weeks of treatment.

    When considering the five subscales of HAMD-17,there were some minor, non-significant differences in the onset of the treatment effect between the different subscales, but all five subscales showed statistically significant improvement after two weeks of treatment in both treatment groups.

    4.2 Limitations

    The 97% ‘efficacy’ of shuganjieyu appears promising but the picture looks quite different when one realizes that only 20% of patients had a 50% or greater improvement in their depressive symptoms over the 6-week trial.In the absence of a full placebo control group or an SSRI comparison group one cannot be certain that the observed improvement in both groups was the result of shuganjieyu treatment -- it could have been related to the placebo effect of being hospitalized. Studies using different types of comparison groups will be needed to resolve this issue.

    This study was conducted in an inpatient setting with patients who had relatively severe depressive symptoms. It is unknown whether or not the outcome would be the same in less-severe, community-based patients. In particular, the use of rTMS, which required daily sessions at a medical setting over several weeks,may not be feasible for most community-based patients.

    The failure to find any significant differences between the two groups may be because we did not use the optimal configuration, frequency, and duration of rTMS. The optimal parameters may be different in elderly individuals, so considerable work will be needed to establish standardized methods for administering rTMS in geriatric depression. Larger studies conducted for longer periods may identify significant differences when rTMS is used as an adjunctive treatment for shuganjieyu, but this would probably only be practical in inpatient settings. There may be specific subgroups of patients for whom rTMS is a useful adjunctive treatment, but larger studies would be needed to compare differences between different subgroups of patients to help identify the subgroups in which rTMS is useful.

    4.3 Implications

    We confirm the efficacy and safety of the Chinese herbal medicine shuganjieyu in the treatment of geriatric depression. However, after 6 weeks of treatment only 20% of the subjects had a significant improvement in their depressive symptoms (defined as a 50% drop in the baseline HAMD-17 score) so the value of this medicine as a first-line treatment for geriatric depression may be limited. Shuganjieyu may, however, be useful as a second-line treatment for elderly individuals who cannot tolerate SSRIs. We did not find that adjunctive treatment with rTMS improved overall outcomes for shuganjieuyu or resulted in a more rapid onset of action,though larger samples and longer follow-up studies may be needed to definitively address this issue.

    Conflict of interest

    The authors declare no conflict of interest.

    Funding

    The authors obtained no funding to support this study.

    Ethics approval

    This study was approved by the ethics committee of Daqing Third Hospital.

    Informed consent

    All participants or their guardians provided informed consent to participate in this study.

    1. Lingworth SA, Burgess PM, Whiteford HA. Affective and anxiety disorders: prevalence, treatment and antidepressant medication use.Aust N Z J Psychiatry. 2010; 44(6): 513-519

    2. Clignet F, van Meijel B, vail Straten A, Cuijpers P. The systematic activation method as a nursing intervention in depressed elderly: a protocol for a multi-centre cluster randomized trial.BMC Psychiatry.2012; 12(1): 144. doi:http://dx.doi.org/10.1186/1471-244X-12-144

    3. Li J. [Efficacy observation of the sertraline treatment combined with Shuganjieyu capsule on the elderly patients with depression].Zhongguo Yi Yao Zhi Nan. 2013; 11(34):495-496. Chinese

    4. Digby G, Machaalany J, Malik P, Methot M, Simpson CS, Redfearn D, et al. Multifactorial QT interval prolongation.Cardiol J. 2010; 17(2): 184-188

    5. Liu SB, Li CF, Wang YF, Li J. [Case-control study of the treatment of Shuganjieyu capsule combined with venlafaxine on the elderly patients with depression].Lin Chuang Jing Shen Yi Xue Za Zhi. 2012; 22(2): 98. Chinese

    6. Song H, Ma JD, Chen YX, Huang SP. [The efficacy of Shuganjieyu capsule combined with venlafaxine in treatment of senile depression].Yi Xue Zong Shu. 2013;19(17): 2302-2308. Chinese. doi: http://dx.doi.org/10.3969/j.issn.1006-2084.2013.17.043

    7. Alexopoulos GS, Kelly RE. Research advances in geriatric depression.World Psychiatry. 2009; 8(3): 140-149

    8. Russo E, Scicchitano F, Whalley BJ, Mazzitello C, Ciriaco M, Esposito S, et al. Hypericumperforatum: pharmacokinetic,mechanism of action, tolerability, and clinical drug-drug interactions.Phytother Res. 2014; 28(5): 643-655. doi:http://dx.doi.org/10.1002/ptr.5050

    9. Dumas R, Padovani R, Richierij R, Lan?on C. [Repetitive transcranial magnetic stimulation in major depression:response factor].Encephale. 2012; 38(4): 360-368. French.doi: http://dx.doi.org/10.1016/j.encep.2011.08.004

    10. Richieri R, Guedj E, Michel P, Lan?on C, Boyer L. Maintenance transcranial magnetic stimulation reduces depression relapse: a propensity-adjusted analysis.J Affect Disord.2013; 151(1): 129-135. doi: http://dx.doi.org/10.1016/j.jad.2013.05.062

    11. Schutter DJ. Quantitative review of the efficacy of slowfrequency magnetic brain stimulation in major depressive disorder.Psychol Med. 2010; 40(11): 1789-1795

    12. World Health Organization.ICD-10 Classifications of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines.Geneva: World Health Organization;1992

    13. Dong HT, Han G, Zhu XC, Guo RJ. [Progress on depression due to liver stagnation and spleen deficiency: a literature review].Huan Qiu Zhong Yi Yao. 2014; 7(2): 46-50. Chinese. doi:http://dx.doi.org/10.3969/j.issn.1674-1749.2014.02.022

    14. Zhang MY. [Manual of Psychiatric Rating Scale]. Changsha:Hunan Science and Technology Press; 1998. p. 121-204.Chinese

    15. Dan B. [Assessment on diagnosis and efficacy of Han Mitton Depression Scale for 136 cases of post-stroke depression].Zhongguo Wu Zhen Xue Za Zhi. 2007; 7(24):5848-5849. Chinese. doi: http://dx.doi.org/10.3969/j.issn.1009-6647.2007.24.129

    16. Chen YY, Wang YJ, Huang Y. [The effects on the score of the each factor of HAMD for mild to moderate depression treated with abdominal acupuncture].Liao Ning Zhong Yi Za Zhi. 2011; 38(5): 981-983. Chinese

    17. Chen JD. [Clinical and neuroimaging studies of depression in elderly]. Hu Nan, Changsha: Central South University; 2008.Chinese

    , 2015-03-18; accepted, 2014-04-09)

    Minmin Xie obtained her bachelor’s degree in medicine from Harbin Medical University (Daqing Campus) in June 2013. She enrolled in a master’s program at Harbin Medical University (Daqing Campus) in 2013 and is currently doing her internship at the Geriatrics Department of the Third Hospital of Daqing. Her research interest is the treatment of geriatric mental disorders.

    中草藥舒肝解郁膠囊單用或聯(lián)合重復(fù)經(jīng)顱磁刺激(rTMS)治療老年期抑郁癥的療效和安全性:一項(xiàng)隨機(jī)對(duì)照研究

    謝敏敏,姜文海,楊海波

    舒肝解郁膠囊;中草藥;重復(fù)經(jīng)顱磁刺激;老年期抑郁癥;中國(guó)

    Background: Pharmacological treatment of geriatric depression is often ineffective because patients cannot tolerate adequate doses of antidepressant medications.Aims: Examine the efficacy and safety of shuganjieyu – the first Chinese herbal medicine approved for the treatment of depression by China’s drug regulatory agency -- with and without adjunctive treatment with repetitive transcranial magnetic stimulation (rTMS) in the treatment of geriatric depression.Methods: Sixty-five inpatients 60 or older who met ICD-10 criteria for depression were randomly assigned to an experimental group (shuganjieyu + rTMS) (n=36) or a control group (shuganjieyu + sham rTMS)(n=29). All participants

    4 capsules of shuganjieyu daily for 6 weeks. rTMS (or sham rTMS)was administered 20 minutes daily, five days a week for 4 weeks. Blinded raters used the Hamilton Rating Scale for Depression (HAMD-17) and the Treatment Emergent Symptom Scale to assess clinical efficacy and safety at baseline and 1, 2, 4, and 6 weeks after starting treatment. Over the six-week trial, there was only one dropout from the experimental group and two dropouts from the control group.Results: None of the patients had serious side effects, but 40% in the experimental group and 50% in the control group experienced minor side effects that all resolved spontaneously. Both groups showed substantial stepwise improvement in depressive symptoms over the 6 weeks. Repeated measures ANOVA found no differences between the two groups. After 6 weeks, 97% of the experimental group had experienced a 25% or greater drop in the level of depression, but only 20% had experience a 50% or greater drop in the level of depression; the corresponding values in the control group were 96% and 19%.There were some minor, non-significant differences in the onset of the treatment effect between the different types of depressive symptoms, but by the second week of treatment all five HAMD-17 subscale scores had improved signi ficantly in both groups Conclusions: The Chinese herbal medicine shuganjieyu is effective and safe in the treatment of geriatric depression, but only a minority of patients have greater than 50% improvement in their depressive symptoms after 6 weeks of treatment. Adjunctive use of rTMS with shuganjieyu does not improve the overall outcome and does not signi ficantly speed up the onset of action of shuganjieyu.

    [Shanghai Arch Psychiatry. 2015; 27(2): 103-110.

    http://dx.doi.org/10.11919/j.issn.1002-0829.214151]

    1Daqing Campus of Harbin Medical University, Daqing, Heilongjiang Province, China

    2The Third People’s Hospital of Daqing, Daqing, Heilongjiang Province, China

    *correspondence: dqjwh@126.com

    背景:由于老年期抑郁癥患者往往不能耐受足量的抗抑郁藥物,所以藥物治療老年抑郁癥的療效不佳。目的:探討舒肝解郁膠囊(中國(guó)藥品監(jiān)督管理部門批準(zhǔn)用于治療抑郁癥的首個(gè)中草藥)單用或聯(lián)合重復(fù)經(jīng)顱磁刺 激(repetitive transcranial magnetic stimula-tion,rTMS)治療老年期抑郁癥的療效和安全性。方法:將65例60歲以上符合ICD-10診斷標(biāo)準(zhǔn)的抑郁癥住院患者隨機(jī)分為研究組(舒肝解郁膠囊+rTMS)(n =36)和對(duì)照組(舒肝解郁膠囊+偽rTMS)(n=29)。所有患者每日服用4粒舒肝解郁膠囊,一共服用6周。rTMS(或偽rTMS)治療20 min/d,每周5 d,共4周。評(píng)估者在不知患者分組情況下,采用漢密爾頓抑郁量表(HAMD-17)和副反應(yīng)量表評(píng)估基線和治療開始后1、2、4、6周的臨床療效和安全性。在6周的研究過(guò)程中,研究組僅有1人脫落,對(duì)照組僅有2人脫落。結(jié)果:沒(méi)有一例患者出現(xiàn)嚴(yán)重不良反應(yīng),但研究組和對(duì)照組中分別有40%和50%的患者出現(xiàn)輕微的不良反應(yīng),均自行緩解。兩組的抑郁癥狀在6周內(nèi)均逐步明顯改善。重復(fù)測(cè)量方差分析沒(méi)有發(fā)現(xiàn)兩組之間有顯著差異。 6周后,研究組97%的患者抑郁程度下降幅度大于等于25%,但只有20%者的下降幅度大于等于50%;對(duì)照組中相應(yīng)的患者比例分別為96%和19%。雖然不同的抑郁癥狀之間治療起效有著輕微的、非顯著性的差異,但是治療第二周后兩組HAMD-17五個(gè)分量表的評(píng)分均顯著改善。結(jié)論:中草藥舒肝解郁膠囊治療老年抑郁癥是有效和安全的,然而只有少數(shù)患者的抑郁癥狀在治療6周后改善程度大于50%。聯(lián)合重復(fù)經(jīng)顱磁刺激治療并沒(méi)有增加舒肝解郁膠囊的總體療效,也沒(méi)有顯著加快后者的起效。

    本文全文中文版從2015年6月6日起在http://dx.doi.org/10.11919/j.issn.1002-0829.214151 可供免費(fèi)閱覽下載

    猜你喜歡
    單用經(jīng)顱中草藥
    經(jīng)顱電刺激技術(shù)對(duì)運(yùn)動(dòng)性疲勞作用效果的研究進(jìn)展
    三味中草藥 消炎效果好
    中草藥制劑育肥豬
    莫西沙星單用與聯(lián)合用藥治療非重癥社區(qū)獲得性肺炎療效比較
    導(dǎo)管主動(dòng)脈瓣置換術(shù)后抗血小板藥單用或雙聯(lián)治療短期并發(fā)癥有效性和安全性的Meta分析
    經(jīng)顱直流電刺激技術(shù)在阿爾茨海默癥治療中的研究進(jìn)展
    經(jīng)顱磁刺激定位方法的研究進(jìn)展
    重復(fù)經(jīng)顱磁刺激對(duì)酒依賴合并焦慮抑郁患者的影響
    中草藥在緩解夏季豬熱應(yīng)激中的研究應(yīng)用
    廣東飼料(2016年7期)2016-12-01 03:43:34
    結(jié)緣中草藥
    最新在线观看一区二区三区| 国产精品一区二区精品视频观看| 国产高清视频在线播放一区| 色综合亚洲欧美另类图片| 99在线人妻在线中文字幕| 免费搜索国产男女视频| 欧美丝袜亚洲另类 | 午夜视频精品福利| 宅男免费午夜| 久久精品国产亚洲av高清一级| 如日韩欧美国产精品一区二区三区| 欧美中文日本在线观看视频| 9191精品国产免费久久| 动漫黄色视频在线观看| 18禁国产床啪视频网站| 一个人观看的视频www高清免费观看 | www.熟女人妻精品国产| 午夜激情av网站| 女人高潮潮喷娇喘18禁视频| 日韩欧美三级三区| 久久久久九九精品影院| 成人三级做爰电影| 亚洲av成人一区二区三| 禁无遮挡网站| 免费不卡黄色视频| 国产精品野战在线观看| 日本黄色视频三级网站网址| 亚洲,欧美精品.| 久久人妻福利社区极品人妻图片| 亚洲人成伊人成综合网2020| 人妻丰满熟妇av一区二区三区| 手机成人av网站| 最好的美女福利视频网| 久久中文字幕人妻熟女| 国产单亲对白刺激| 欧美乱色亚洲激情| 12—13女人毛片做爰片一| 一进一出抽搐gif免费好疼| 国产成人欧美在线观看| 亚洲av第一区精品v没综合| 午夜福利,免费看| 中文字幕人成人乱码亚洲影| 在线观看一区二区三区| 久久精品国产亚洲av香蕉五月| 他把我摸到了高潮在线观看| 国产免费av片在线观看野外av| www.999成人在线观看| 深夜精品福利| 变态另类丝袜制服| 国产欧美日韩精品亚洲av| 88av欧美| 亚洲精品美女久久久久99蜜臀| 亚洲av成人av| 国产精品,欧美在线| 日韩欧美三级三区| 久久午夜亚洲精品久久| 久久青草综合色| 亚洲成人免费电影在线观看| 精品乱码久久久久久99久播| 亚洲精品久久国产高清桃花| 国内久久婷婷六月综合欲色啪| 色婷婷久久久亚洲欧美| 亚洲国产看品久久| 69av精品久久久久久| 国产区一区二久久| 国产伦一二天堂av在线观看| 精品久久久久久,| 成人免费观看视频高清| 精品无人区乱码1区二区| 精品国内亚洲2022精品成人| 国产一级毛片七仙女欲春2 | 最近最新中文字幕大全免费视频| 午夜福利成人在线免费观看| 亚洲自偷自拍图片 自拍| 村上凉子中文字幕在线| 精品免费久久久久久久清纯| 成人国语在线视频| 欧美日本视频| 丁香欧美五月| 免费搜索国产男女视频| 多毛熟女@视频| 成人国产综合亚洲| 日本欧美视频一区| 久久亚洲真实| 国产日韩一区二区三区精品不卡| 麻豆久久精品国产亚洲av| 国产xxxxx性猛交| 老汉色av国产亚洲站长工具| 亚洲精品国产精品久久久不卡| 麻豆av在线久日| 亚洲第一欧美日韩一区二区三区| 久久 成人 亚洲| 美女国产高潮福利片在线看| 好男人电影高清在线观看| 男女下面进入的视频免费午夜 | 精品国产超薄肉色丝袜足j| 亚洲精品中文字幕在线视频| 国产精品福利在线免费观看| 午夜免费成人在线视频| 日韩中字成人| 男人舔女人下体高潮全视频| 免费电影在线观看免费观看| 有码 亚洲区| 久久精品综合一区二区三区| 国产黄色小视频在线观看| 欧美日韩乱码在线| 久久久国产成人免费| 亚洲av成人精品一区久久| 亚洲成人免费电影在线观看| 国产av不卡久久| 精品一区二区三区视频在线| 99热这里只有是精品50| 色哟哟哟哟哟哟| 国产精品人妻久久久影院| 亚洲av免费高清在线观看| 国产成人a区在线观看| 免费av不卡在线播放| 黄色女人牲交| 俺也久久电影网| 乱码一卡2卡4卡精品| 一区二区三区激情视频| 有码 亚洲区| 18禁黄网站禁片午夜丰满| 免费一级毛片在线播放高清视频| 久久人人精品亚洲av| 日韩强制内射视频| 亚洲av不卡在线观看| 免费无遮挡裸体视频| 少妇丰满av| 一个人观看的视频www高清免费观看| 欧洲精品卡2卡3卡4卡5卡区| 日本-黄色视频高清免费观看| 天堂动漫精品| 97超级碰碰碰精品色视频在线观看| 欧美高清成人免费视频www| 欧美又色又爽又黄视频| 国产精品女同一区二区软件 | 草草在线视频免费看| 色播亚洲综合网| 欧美日韩亚洲国产一区二区在线观看| 99视频精品全部免费 在线| 亚洲一级一片aⅴ在线观看| 桃红色精品国产亚洲av| 天堂影院成人在线观看| 久久久久久九九精品二区国产| 琪琪午夜伦伦电影理论片6080| 色视频www国产| 看十八女毛片水多多多| 亚洲自偷自拍三级| 色视频www国产| 亚洲精品一卡2卡三卡4卡5卡| 日本精品一区二区三区蜜桃| 国产精品久久久久久久久免| av福利片在线观看| 国产男人的电影天堂91| 午夜福利成人在线免费观看| 中文字幕av成人在线电影| 日韩欧美免费精品| 精品一区二区三区av网在线观看| 国产真实伦视频高清在线观看 | 久久热精品热| 天天躁日日操中文字幕| 天堂网av新在线| 日本与韩国留学比较| 欧美成人a在线观看| 精品久久久噜噜| 亚洲精品一区av在线观看| 亚洲精品影视一区二区三区av| 精品久久久久久久久久免费视频| 亚洲精品日韩av片在线观看| 欧美色视频一区免费| 亚洲成av人片在线播放无| 最新中文字幕久久久久| 国产人妻一区二区三区在| 亚洲,欧美,日韩| 国产精品免费一区二区三区在线| 性欧美人与动物交配| 欧美日韩综合久久久久久 | 亚洲精品乱码久久久v下载方式| 看十八女毛片水多多多| 久久精品久久久久久噜噜老黄 | 日韩av在线大香蕉| 精品午夜福利视频在线观看一区| 婷婷精品国产亚洲av| 午夜影院日韩av| 最后的刺客免费高清国语| 欧美高清性xxxxhd video| 色5月婷婷丁香| 大型黄色视频在线免费观看| 我要看日韩黄色一级片| 国产精华一区二区三区| 亚洲,欧美,日韩| 国产av在哪里看| 欧美一区二区国产精品久久精品| 国产视频内射| 国产伦在线观看视频一区| 国产私拍福利视频在线观看| 亚洲av免费高清在线观看| 久久人妻av系列| 又黄又爽又刺激的免费视频.| 免费人成在线观看视频色| 日日摸夜夜添夜夜添av毛片 | 国内毛片毛片毛片毛片毛片| 午夜精品久久久久久毛片777| 日韩国内少妇激情av| 欧美日本亚洲视频在线播放| 狠狠狠狠99中文字幕| 午夜激情欧美在线| 国产色爽女视频免费观看| 亚洲精品在线观看二区| 欧美日韩中文字幕国产精品一区二区三区| 国产人妻一区二区三区在| 亚洲在线观看片| 我的老师免费观看完整版| 99热网站在线观看| 亚洲精品456在线播放app | 婷婷色综合大香蕉| 国产美女午夜福利| 中文资源天堂在线| 亚洲精品日韩av片在线观看| 亚洲av熟女| 国产日本99.免费观看| 日韩一区二区视频免费看| 麻豆久久精品国产亚洲av| 天堂动漫精品| 欧美色视频一区免费| 十八禁国产超污无遮挡网站| 草草在线视频免费看| 国模一区二区三区四区视频| 又黄又爽又刺激的免费视频.| 身体一侧抽搐| 变态另类丝袜制服| 中文字幕免费在线视频6| 欧美激情久久久久久爽电影| 婷婷六月久久综合丁香| 欧美成人一区二区免费高清观看| 老司机深夜福利视频在线观看| 亚洲真实伦在线观看| 国产一区二区三区在线臀色熟女| 日本撒尿小便嘘嘘汇集6| 大又大粗又爽又黄少妇毛片口| avwww免费| 毛片一级片免费看久久久久 | 亚洲午夜理论影院| 91av网一区二区| 深夜精品福利| av黄色大香蕉| 日韩,欧美,国产一区二区三区 | 五月伊人婷婷丁香| 久久久久久久久大av| 美女高潮喷水抽搐中文字幕| 琪琪午夜伦伦电影理论片6080| 九九久久精品国产亚洲av麻豆| 国产蜜桃级精品一区二区三区| 99在线人妻在线中文字幕| 乱人视频在线观看| 日本 av在线| 国产免费av片在线观看野外av| 亚洲一级一片aⅴ在线观看| 欧美性猛交黑人性爽| 男女之事视频高清在线观看| 午夜激情福利司机影院| 91狼人影院| 亚洲自拍偷在线| 一个人观看的视频www高清免费观看| 国内精品美女久久久久久| АⅤ资源中文在线天堂| 高清毛片免费观看视频网站| 99久久九九国产精品国产免费| 午夜a级毛片| 嫩草影院入口| 亚洲欧美日韩高清在线视频| 亚洲 国产 在线| 美女xxoo啪啪120秒动态图| 女人被狂操c到高潮| 成人国产综合亚洲| 我的女老师完整版在线观看| 欧美极品一区二区三区四区| 精品福利观看| 国产男人的电影天堂91| 女人被狂操c到高潮| 大型黄色视频在线免费观看| av视频在线观看入口| 欧美国产日韩亚洲一区| 999久久久精品免费观看国产| 久久久久久久精品吃奶| 亚洲天堂国产精品一区在线| 国产爱豆传媒在线观看| 69人妻影院| 九九爱精品视频在线观看| 亚洲精品一区av在线观看| 亚洲黑人精品在线| 精品国内亚洲2022精品成人| 22中文网久久字幕| 日本欧美国产在线视频| 国产伦在线观看视频一区| 色噜噜av男人的天堂激情| 在线观看午夜福利视频| 欧美绝顶高潮抽搐喷水| 国产精品,欧美在线| 国产真实乱freesex| 国产亚洲精品av在线| 女生性感内裤真人,穿戴方法视频| 午夜激情福利司机影院| 国语自产精品视频在线第100页| 在线免费观看的www视频| 免费观看的影片在线观看| 老熟妇乱子伦视频在线观看| 97超视频在线观看视频| 国产真实乱freesex| 韩国av一区二区三区四区| 精华霜和精华液先用哪个| 99热这里只有是精品在线观看| 国产精品一区二区三区四区免费观看 | 午夜久久久久精精品| 在线观看av片永久免费下载| 亚洲七黄色美女视频| 国产在视频线在精品| 成人av一区二区三区在线看| 午夜爱爱视频在线播放| 亚洲国产精品合色在线| 国产av不卡久久| 国产精品永久免费网站| 午夜福利高清视频| 狠狠狠狠99中文字幕| 99热这里只有是精品50| 亚洲av.av天堂| 在线免费观看不下载黄p国产 | 亚洲精品亚洲一区二区| 给我免费播放毛片高清在线观看| 日韩一区二区视频免费看| 精品久久久久久,| 中国美女看黄片| 乱码一卡2卡4卡精品| 久久99热这里只有精品18| 亚洲欧美日韩高清专用| 成人永久免费在线观看视频| 在线免费观看的www视频| 中文字幕人妻熟人妻熟丝袜美| 国产免费一级a男人的天堂| a级毛片a级免费在线| 国产单亲对白刺激| 婷婷色综合大香蕉| 18禁黄网站禁片午夜丰满| 日日夜夜操网爽| 又爽又黄a免费视频| 日韩精品青青久久久久久| ponron亚洲| 美女高潮喷水抽搐中文字幕| 欧美性感艳星| 精品无人区乱码1区二区| 精品一区二区三区av网在线观看| 国产白丝娇喘喷水9色精品| 国产av在哪里看| a级毛片a级免费在线| 俺也久久电影网| 亚洲avbb在线观看| 在线播放无遮挡| 99视频精品全部免费 在线| 男人舔女人下体高潮全视频| 久久精品综合一区二区三区| 最近视频中文字幕2019在线8| 日韩av在线大香蕉| 欧洲精品卡2卡3卡4卡5卡区| 亚洲性久久影院| 1000部很黄的大片| 日日撸夜夜添| 成人午夜高清在线视频| 久久久色成人| 日本在线视频免费播放| 两性午夜刺激爽爽歪歪视频在线观看| 久久久久久九九精品二区国产| 五月玫瑰六月丁香| 亚洲精品久久国产高清桃花| 俺也久久电影网| 色尼玛亚洲综合影院| 内射极品少妇av片p| 91久久精品电影网| av天堂在线播放| 丰满的人妻完整版| 免费大片18禁| 亚洲欧美日韩高清专用| 乱码一卡2卡4卡精品| 成人国产综合亚洲| 少妇人妻一区二区三区视频| 国产精品自产拍在线观看55亚洲| 精品人妻熟女av久视频| aaaaa片日本免费| 精品国内亚洲2022精品成人| 又紧又爽又黄一区二区| 热99在线观看视频| 日日干狠狠操夜夜爽| 精品一区二区三区视频在线| 欧美成人免费av一区二区三区| 99精品在免费线老司机午夜| 国产精品一区二区性色av| 国产主播在线观看一区二区| 日本精品一区二区三区蜜桃| 欧美在线一区亚洲| 一卡2卡三卡四卡精品乱码亚洲| 国产伦人伦偷精品视频| 国产美女午夜福利| 联通29元200g的流量卡| 日韩中文字幕欧美一区二区| 成人国产麻豆网| 精品免费久久久久久久清纯| 1024手机看黄色片| 美女 人体艺术 gogo| 成人一区二区视频在线观看| 国产乱人伦免费视频| 热99在线观看视频| 色播亚洲综合网| 亚洲人成伊人成综合网2020| 亚洲人成网站在线播| 老熟妇乱子伦视频在线观看| 麻豆成人av在线观看| 2021天堂中文幕一二区在线观| 深夜精品福利| 亚洲欧美激情综合另类| 欧美不卡视频在线免费观看| 九九久久精品国产亚洲av麻豆| 国产精品久久视频播放| 99久久成人亚洲精品观看| 欧美日韩综合久久久久久 | 天堂网av新在线| 国产一区二区三区视频了| 久久久久久久久大av| 在线免费十八禁| 色5月婷婷丁香| 亚洲乱码一区二区免费版| 日韩欧美免费精品| 国产精品久久电影中文字幕| 国产精品国产高清国产av| 久久精品夜夜夜夜夜久久蜜豆| 亚洲七黄色美女视频| 女的被弄到高潮叫床怎么办 | 亚洲avbb在线观看| 久久精品国产亚洲av涩爱 | 精品人妻1区二区| av在线天堂中文字幕| 精品人妻熟女av久视频| 日韩欧美在线乱码| 日日啪夜夜撸| 欧美一区二区亚洲| 给我免费播放毛片高清在线观看| 精品午夜福利视频在线观看一区| 亚洲成av人片在线播放无| 日日啪夜夜撸| 夜夜夜夜夜久久久久| 十八禁国产超污无遮挡网站| 99视频精品全部免费 在线| 91麻豆精品激情在线观看国产| 18禁在线播放成人免费| 亚洲av免费高清在线观看| 99热这里只有是精品50| av在线亚洲专区| 夜夜看夜夜爽夜夜摸| 男女边吃奶边做爰视频| 在现免费观看毛片| 精品久久久久久久人妻蜜臀av| 国产精品久久久久久亚洲av鲁大| 日日干狠狠操夜夜爽| 一本精品99久久精品77| 啦啦啦观看免费观看视频高清| 国产高清视频在线播放一区| 亚洲一级一片aⅴ在线观看| 男人和女人高潮做爰伦理| av专区在线播放| 国产高清视频在线播放一区| 日韩强制内射视频| 国产中年淑女户外野战色| 成人欧美大片| 搞女人的毛片| 亚洲成人中文字幕在线播放| 国产精品自产拍在线观看55亚洲| 97热精品久久久久久| 亚洲在线自拍视频| 又粗又爽又猛毛片免费看| 美女xxoo啪啪120秒动态图| 美女高潮的动态| 亚洲欧美日韩东京热| 男女下面进入的视频免费午夜| 欧美日韩乱码在线| 欧美另类亚洲清纯唯美| 中文字幕高清在线视频| 午夜福利18| 欧美激情在线99| 久久草成人影院| 欧美精品啪啪一区二区三区| 久久精品久久久久久噜噜老黄 | 日本欧美国产在线视频| 国产综合懂色| 91久久精品电影网| 国产一区二区在线av高清观看| 亚洲欧美日韩高清专用| 国产激情偷乱视频一区二区| 国产真实伦视频高清在线观看 | 淫秽高清视频在线观看| 夜夜夜夜夜久久久久| 亚洲性久久影院| 午夜福利18| 亚洲av第一区精品v没综合| 老司机午夜福利在线观看视频| 国产亚洲精品av在线| eeuss影院久久| 国产精品女同一区二区软件 | 搡老熟女国产l中国老女人| 国产高清激情床上av| 一个人观看的视频www高清免费观看| 欧美精品国产亚洲| 精品人妻一区二区三区麻豆 | 免费一级毛片在线播放高清视频| 亚洲av免费在线观看| 精品久久久久久久久久久久久| 97人妻精品一区二区三区麻豆| 久久精品国产99精品国产亚洲性色| 国产乱人视频| 午夜亚洲福利在线播放| 精品久久久久久成人av| 国产精品久久久久久久电影| 高清日韩中文字幕在线| 非洲黑人性xxxx精品又粗又长| 两性午夜刺激爽爽歪歪视频在线观看| 丰满人妻一区二区三区视频av| 国产精品美女特级片免费视频播放器| 国产成人一区二区在线| 搡女人真爽免费视频火全软件 | 99久久无色码亚洲精品果冻| 亚洲天堂国产精品一区在线| ponron亚洲| 听说在线观看完整版免费高清| 两人在一起打扑克的视频| 黄色一级大片看看| 91麻豆精品激情在线观看国产| 精品一区二区三区视频在线| 日韩欧美在线乱码| 精品国产三级普通话版| 免费人成视频x8x8入口观看| 亚洲av不卡在线观看| 特级一级黄色大片| 久久精品国产亚洲av香蕉五月| 精品欧美国产一区二区三| 日韩大尺度精品在线看网址| 2021天堂中文幕一二区在线观| 毛片女人毛片| 亚洲精华国产精华液的使用体验 | 夜夜看夜夜爽夜夜摸| 嫩草影院精品99| 精品午夜福利视频在线观看一区| 国产熟女欧美一区二区| 麻豆国产97在线/欧美| 国产亚洲欧美98| 免费无遮挡裸体视频| 床上黄色一级片| 久久草成人影院| 国产精品一区二区性色av| 亚洲黑人精品在线| 精品一区二区三区av网在线观看| av中文乱码字幕在线| 午夜福利在线观看吧| 99热这里只有是精品50| 五月伊人婷婷丁香| 亚洲av熟女| 午夜免费男女啪啪视频观看 | 成年女人永久免费观看视频| 久久九九热精品免费| 国产精品不卡视频一区二区| 久久亚洲精品不卡| 乱系列少妇在线播放| 国产成人一区二区在线| 国产av不卡久久| 一级黄片播放器| 97人妻精品一区二区三区麻豆| 99久久精品国产国产毛片| 日韩欧美在线二视频| 久久久午夜欧美精品| 毛片一级片免费看久久久久 | 久久久久性生活片| 国产高清不卡午夜福利| 制服丝袜大香蕉在线| 亚洲在线观看片| 亚洲欧美日韩无卡精品| www.www免费av| 真实男女啪啪啪动态图| 国产乱人视频| 亚洲欧美日韩卡通动漫| 亚洲图色成人| 国产又黄又爽又无遮挡在线| 日本五十路高清| 久久久久九九精品影院| 国产精品不卡视频一区二区| 在线免费观看的www视频| 精品日产1卡2卡| 久久久久久九九精品二区国产| 日韩欧美免费精品| 国产色爽女视频免费观看| 国产高清不卡午夜福利| 观看美女的网站| 国产 一区 欧美 日韩| 一区福利在线观看| 亚洲av免费高清在线观看| 不卡视频在线观看欧美| 国产国拍精品亚洲av在线观看| 亚洲欧美精品综合久久99| ponron亚洲| 床上黄色一级片| 欧美成人免费av一区二区三区| 在线观看av片永久免费下载| 国产精品女同一区二区软件 | 久久99热6这里只有精品| 国产精品1区2区在线观看.| 亚洲精品国产成人久久av| 特大巨黑吊av在线直播| 成年版毛片免费区| 舔av片在线|